aTyr Pharma to Present at Upcoming Investor Conferences in May
Details of the events are as follows:
Presenter: Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer
Format: Fireside Chat
Presenter: Ashlee Dunston, Director, Investor Relations and Corporate Communications
Format: Corporate Presentation
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. Following the events, a replay of each presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com.
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
Director, Investor Relations and Corporate Communications
Source: aTyr Pharma, Inc.